Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism
Top Cited Papers
Open Access
- 20 March 2014
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 123 (12), 1794-1801
- https://doi.org/10.1182/blood-2013-12-512681
Abstract
It takes about 3 months to complete “active treatment” of venous thromboembolism (VTE), with further treatment serving to prevent new episodes of thrombosis (“pure secondary prevention”). Consequently, VTE should generally be treated for either 3 months or indefinitely (exceptions will be described in the text). The decision to stop anticoagulants at 3 months or to treat indefinitely is dominated by the long-term risk of recurrence, and secondarily influenced by the risk of bleeding and by patient preference. VTE provoked by a reversible risk factor, or a first unprovoked isolated distal (calf) deep vein thrombosis (DVT), has a low risk of recurrence and is usually treated for 3 months. VTE associated with active cancer, or a second unprovoked VTE, has a high risk of recurrence and is usually treated indefinitely. The decision to stop anticoagulants at 3 months or to treat indefinitely is more finely balanced after a first unprovoked proximal DVT or pulmonary embolism (PE). Indefinite anticoagulation is often chosen if there is a low risk of bleeding, whereas anticoagulation is usually stopped at 3 months if there is a high risk of bleeding. The decision to continue anticoagulation indefinitely after a first unprovoked proximal DVT or PE is strengthened if the patient is male, the index event was PE rather than DVT, and/or d-dimer testing is positive 1 month after stopping anticoagulant therapy.Keywords
This publication has 65 references indexed in Scilit:
- Apixaban for Extended Treatment of Venous ThromboembolismThe New England Journal of Medicine, 2013
- Extended Use of Dabigatran, Warfarin, or Placebo in Venous ThromboembolismThe New England Journal of Medicine, 2013
- Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTHJournal of Thrombosis and Haemostasis, 2012
- A conceptual framework for two phases of anticoagulant treatment of venous thromboembolismJournal of Thrombosis and Haemostasis, 2012
- The treatment of venous thromboembolism with low-molecular-weight heparinsThrombosis and Haemostasis, 2012
- Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapyCMAJ : Canadian Medical Association Journal, 2008
- Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trialBMJ, 2007
- Post‐thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 monthsJournal of Thrombosis and Haemostasis, 2006
- Treatment of venous thromboembolism with vitamin K antagonists: patients’ health state valuations and treatment preferencesThrombosis and Haemostasis, 2004
- Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolismThe Lancet, 1992